The agreement allows AuraVax to exclusively license patents utilizing intellectual property related to the novel vaccine platform. The company intends to advance the technology to create vaccines that address multiple respiratory viruses, including SARS-CoV-2.

AuraVax is based out of Houston and was created by a professor at the University of Houston. The company's first goal is to create a more effective way to vaccinate against COVID-19.

Can SARS-CoV antibodies be used to develop universal coronavirus vaccines?
Can antibodies developed against SARS-CoV during the 2003 outbreak be used to prevent infection by SARS-CoV-2? In an October 9 study published in Science...

Will mutation of the SARS-CoV-2 virus affect vaccine effectiveness?
What impact will mutation of the SARS-CoV-2 virus have on the effectiveness of COVID-19 vaccines that are in development? In a new study published in...

FDA issues guidance on submitting EUA requests for COVID-19 vaccines
The U.S. Food and Drug Administration (FDA) on October 6 issued a new guidance with recommendations for developers of COVID-19 vaccines regarding the...

Passive vaccines with mAbs may be effective for COVID-19
Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially...

Heated nickel foam HVAC filters could protect against SARS-CoV-2
New "catch and kill" air filters can instantly and efficiently kill SARS-CoV-2, the virus responsible for COVID-19. The details of the nickel foam-based...